We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-4.94%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.07B
AUM Growth
-$107M
Cap. Flow
+$22.9M
Cap. Flow %
0.75%
Top 10 Hldgs %
75.54%
Holding
110
New
22
Increased
17
Reduced
17
Closed
30

Top Buys

Rank Stock Value
1
HOUS
Anywhere Real Estate
HOUS
+$9.05M
2
TEX icon
Terex
TEX
+$8.34M
3
UAL icon
United Airlines
UAL
+$8.05M
4
GS icon
Goldman Sachs
GS
+$6.44M
5
MTOR
MERITOR, Inc.
MTOR
+$5.8M

Top Sells

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$26M
2
AAPL icon
Apple
AAPL
+$23.2M
3
MET icon
MetLife
MET
+$18.3M
4
ONIT
Onity Group
ONIT
+$17.6M
5
ACOR
Acorda Therapeutics
ACOR
+$14.5M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 35.8%
2 Healthcare 25.27%
3 Industrials 0.67%
4 Financials 0.63%
5 Real Estate 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WW
1
DELISTED
WW International
WW
$1.07B 34.98%
28,749,089
– –
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.04B
$603M 19.63%
36,196,019
– –
SPY icon
3
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$252M 8.2%
1,500,000
+900,000
+150% +$151M
GE icon
4
CALL
GE Aerospace
GE
$377B
$90.8M 2.96%
792,916
+500,789
+171% +$57.4M
AAPL icon
5
CALL
Apple
AAPL
$4.99T
$83.4M 2.72%
4,900,000
+980,000
+25% +$16.2M
AUXL
6
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$48M 1.56%
2,637,200
– –
QCOM icon
7
CALL
Qualcomm
QCOM
$172B
$47.1M 1.53%
700,000
-100,000
-13% -$6.56M
FURX
8
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$42.7M 1.39%
971,051
+56,609
+6% +$2.34M
WFC icon
9
CALL
Wells Fargo
WFC
$263B
$41.3M 1.35%
1,000,000
+800,000
+400% +$34.1M
ACOR
10
DELISTED
Acorda Therapeutics
ACOR
$37.5M 1.22%
9,126
-3,374
-27% -$14.5M
JPM icon
11
CALL
JPMorgan Chase
JPM
$950B
$35.9M 1.17%
700,000
+100,000
+17% +$5.36M
LLY icon
12
CALL
Eli Lilly
LLY
$1.09T
$30.2M 0.98%
600,000
– –
YUM icon
13
CALL
Yum! Brands
YUM
$41.4B
$28.6M 0.93%
556,400
+278,200
+100% +$14.4M
IMGN
14
DELISTED
Immunogen Inc
IMGN
$28.1M 0.91%
1,650,000
-50,000
-3% -$879K
TEVA icon
15
CALL
Teva Pharmaceuticals
TEVA
$36.9B
$26.4M 0.86%
700,000
– –
ONIT
16
CALL
Onity Group
ONIT
$341M
$25.1M 0.82%
30,000
+6,667
+29% +$5.03M
BAC icon
17
CALL
Bank of America
BAC
$439B
$24.1M 0.79%
1,750,000
+250,000
+17% +$3.57M
NKTR icon
18
Nektar Therapeutics
NKTR
$2.39B
$24M 0.78%
153,333
-13,334
-8% -$2.47M
PEP icon
19
CALL
PepsiCo
PEP
$195B
$23.9M 0.78%
+300,000
New +$24.7M
MRK icon
20
CALL
Merck
MRK
$326B
$23.8M 0.78%
524,000
-314,400
-38% -$14.4M
M icon
21
CALL
Macy's
M
$6.62B
$23.8M 0.77%
+550,000
New +$25.7M
AMGN icon
22
CALL
Amgen
AMGN
$212B
$22.4M 0.73%
200,000
+150,000
+300% +$16.3M
C icon
23
CALL
Citigroup
C
$222B
$19.4M 0.63%
400,000
+100,000
+33% +$5.06M
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
$18.7M 0.61%
3,000,000
– –
MJN
25
CALL
DELISTED
Mead Johnson Nutrition Company
MJN
$18.6M 0.6%
250,000
+50,000
+25% +$3.75M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2013 Portfolio in Review

As of Q3 2013, Artal Group held 110 positions worth $3.07B, down 3.4% from $3.18B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Artal Group's Q3 2013 filing shows 22 new, 17 increased, 17 reduced and 30 closed positions. Its largest new stake was Anywhere Real Estate: 200,000 shares worth $8.6M. The largest sale was ONYX PHARMACEUTICALS INC, an estimated $26M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 36% of assets, down from 42% a quarter earlier, followed by Healthcare and Industrials.

  • Artal Group's largest Q3 2013 buy was Anywhere Real Estate: 200,000 shares worth $8.6M.
  • Artal Group added most to Ford in Q3 2013, an estimated $5.07M increase.
  • Artal Group's biggest Q3 2013 reduction was Acorda Therapeutics, cutting an estimated $14.5M.
  • Artal Group fully exited ONYX PHARMACEUTICALS INC in Q3 2013, selling an estimated $26M.
  • Artal Group's ten largest holdings make up 76% of its $3.07B portfolio in Q3 2013.
  • Artal Group opened 22 new positions and closed 30 in Q3 2013.
  • Artal Group's portfolio value fell 3.4% quarter-over-quarter to $3.07B.

Based on Artal Group's 13F filing for Q3 2013, filed 14 Nov 2013.